Author

K. W. Teng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

A. Koide· 4 shared S. Koide· 4 shared T. Hattori· 4 shared L. A. Romero· 3 shared T. Panchenko· 3 shared K. A. Stapleford· 2 shared M. I. Samanovic· 2 shared M. J. Mulligan· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

A. Koide

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity

A. Koide, T. Panchenko, C. Wang, S. A. Thannickal, L. A. Romero, K. W. Teng, F.-Z. Li, P. Akkapeddi, A. D. Corrado, J. Caro, C. Diefenbach, M. I. Samanovic, M. J. Mulligan, T. Hattori, K. A. Stapleford, , S. Koide

This paper introduces a 2D-MBBA assay for SARS-CoV-2 serology profiling and uses machine learning to predict neutralization capacity from antibody profiles.

bioRxiv · Aug 3, 2021 · PreprintImmunology

The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition

T. Hattori, A. Koide, T. Panchenko, L. A. Romero, K. W. Teng, T. Tada, N. R. Landau, S. Koide

This study investigates antibody targeting of the ACE2-binding interface of SARS-CoV-2 Spike, finding that only a small fraction of RBD-binding antibodies target this region, suggesting it is less immunogenic.

bioRxiv · Nov 3, 2020Biochemistry

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors

C. Fedele, S. Li, K. W. Teng, C. Foster, D. Peng, H. Ran, P. Mita, M. Geer, T. Hattori, A. Koide, Y. Wang, K. H. Tang, J. Leinwand, W. Wang, B. Diskin, , B. G. Neel

This study shows that combining SHP2 inhibitors with KRASG12C inhibitors enhances efficacy in PDAC and NSCLC by overcoming resistance and remodeling the tumor microenvironment.

Journal of Experimental Medicine · Oct 8, 2020Peer-reviewedCancer Biology

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.

M. G. Noval, M. E. Kaczmarek, A. Koide, B. A. Rodriguez-Rodriguez, P. Louie, T. Tada, T. Hattori, T. Panchenko, L. A. Romero, K. W. Teng, A. Bazley, M. de Vries, M. I. Samanovic, J. N. Weiser, I. Aifantis, , K. A. Stapleford

The paper assesses neutralization capacity and antibody titers against SARS-CoV-2 antigens in recovered healthcare workers, finding that high titers of multiple isotypes correlate with neutralization.

bioRxiv · Aug 15, 2020 · PreprintMicrobiology